Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

NCT02873286
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
55 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
12
States / cities
Redding, California • San Diego, California • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

NCT00262041
View directory record Official record
Conditions
Prevention of Meningococcal Disease
Interventions
MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY-CRM conjugate vaccine, unadjuvanted, MenACWY polysaccharide vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 17 Years
Enrollment
524 participants
Timeline
2004 – 2006
U.S. locations
3
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

NCT04590066
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
734,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19

NCT04784767
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Biological · Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 18, 2026, 2:02 AM EDT
Recruiting Phase 4 Interventional

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

NCT04588077
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease
Interventions
Heplisav-B Injectable Product, 2-dose regimen, Heplisav-B Injectable Product, 3-dose regimen
Biological
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 18, 2026, 2:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study

NCT00672035
View directory record Official record
Conditions
Traveler's Diarrhea
Interventions
Biological: heat-labile enterotoxin of E. coli (LT)
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
5
States / cities
Davis, California • Bingham Farms, Michigan • Cortland, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

NCT02773979
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Chloroquine, PfSPZ (NF54) Challenge, Placebo
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

NCT01272180
View directory record Official record
Conditions
Invasive Meningococcal Disease
Interventions
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV., Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV., Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine., Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

NCT04811664
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Moderna COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 29 Years
Enrollment
1,923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634
View directory record Official record
Conditions
Botulism Vaccine
Interventions
Placebo (USP sterile saline for injection), rBV A/B-40 vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm

NCT00076817
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV (vCP205)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 18, 2026, 2:02 AM EDT
Active, not recruiting Not applicable Interventional

Kaiser Colorado Flu Nudge

NCT07372950
View directory record Official record
Conditions
Influenza, Vaccination
Interventions
Behavioral economics framed test messaging
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
6 Months and older
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

NCT04144179
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3, Quadrivalent RIV with H3 strain 4, Quadrivalent RIV with 2018-2019 NH H3 strain
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 30 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Hollywood, Florida • Rochester, New York • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

NCT03058692
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 18, 2026, 2:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

NCT00001539
View directory record Official record
Conditions
Lyme Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 18, 2026, 2:02 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

NCT07500506
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
7 Years and older
Enrollment
1,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
19
States / cities
Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 2:02 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

NCT07003984
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP vaccine, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
1 Year to 11 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
8
States / cities
Fountain Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

NCT06805487
View directory record Official record
Conditions
Zika Virus
Interventions
TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 18, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
North Hollywood, California • San Diego, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 18, 2026, 2:02 AM EDT